Innovating Works

EISAI

Desconocido
PHAGO: Inflammation and AD modulating microglia function focussing on TREM2 and CD33 Sofia ref. 115976 EISAI LIMITED participó en un H2020 H2020-JTI-IMI2-2015-05-two-stage Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaqu...
2016-12-16 - 2022-04-30 | Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... EISAI LIMITED participó en un FP6 PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
2010-01-01 - 2015-12-31 | Financiado
PHARMA-COG: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the earl... EISAI LIMITED participó en un FP7 PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.